<DOC>
	<DOC>NCT02792920</DOC>
	<brief_summary>To compare early and late clinical outcomes with everolimus-eluting cobalt-chromium stent in patients with ST-elevation acute myocardial infarction, as well as identify the characteristics and efficacy of CoCr-EES. Also, OCT sub-analysis will be conducted</brief_summary>
	<brief_title>Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>1. Patients with STEMI who are able to undergo CoCrEES implantation. 2. Patients with no history of PCI in the target vessel 3. Patients who are 20 or older at the time of informed consent 4. Patients who provided written informed consent by himself/herself 5. Patients who are judged by their treating physician to be able to undergo PCI with CoCrEES 6. Patients for whom thrombus aspiration prior to CoCrEES implantation can be recommended 7. Patients who meet all the following vascular inclusion criteria i.Patients with target lesion in native coronary artery ii.Patients with visual maximum vessel diameter of the target stent site in target lesion 8. Patients were obtained finally revascularization of TIMI 3 by visual observation in the target vessel 9. Patients who are able to treat with CoCrEES the diameter 2.5mm or more and 3.5mm or less and the length of 8mm or more and 28mm or less. 1. Patients participating in the other ongoing registry or clinical study(except postmarketing surveillance of CoCrEES), or receiving treatment which may impact on endpoints of this study. 2. Patients presenting with cardiogenic shock 3. Patients for whom 12month and 36month CAG and clinical follow up is considered difficult (patient's residence should also be taken into account) 4. Patients with responsible lesion in left main trunk 5. Patients with renal insufficiency or with chronic renal failure with serum creatinine level of 2.0mg/dL or higher at visit 6. Patients on hemodialysis 7. Patients with a known history of adverse drug reactions to aspirin, or clopidogrel or prasugrel (This may not apply if safety of ticlopidine is confirmed as an alternative drug.) 8. Patients who are below the age of 20 9. Women who were positive in pregnancy test or wish to become pregnant during study duration 10. Patients who newly developed AMI attributable to the prior stented site 11. Patients with a known history of allergy to drug, polymer, metal, and other materials used in CoCrEES 12. Patients diagnosed with hepatic insufficiency 13. Patients with target lesion in saphenous vein graft 14. Patients with active malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>